MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%. MZL in Colombian patients exhibits varied ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS). The cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.